6533b850fe1ef96bd12a840a

RESEARCH PRODUCT

The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer.

Antonio RussoSergio PalmeriVittorio GebbiaLuciano RausaNicolo' Gebbia

subject

0301 basic medicineOncologyMalemedicine.medical_specialtyLung Neoplasms030106 microbiologyDisease03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerEtoposideAgedEtoposidePharmacologyCisplatinPerformance statusbusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRegimenInfectious DiseasesOncology030220 oncology & carcinogenesisFemaleNon small cellCisplatinbusinessmedicine.drug

description

Twenty-one patients with histologically proven advanced or disseminated non-small cell lung cancer were treated with cisplatinum 80 mg/m2 i.v. day 1 and etoposide (VP16) 80 mg/m2 i.v. day 1- greater than 3.15 patients were evaluable for response. One patient (6.6%) achieved a complete response, 4 (26.7%) a partial response and 6 (40.0%) a stabilization of disease. Four patients (26.7%) progressed. An improvement in performance status was obtained in more than 50% of cases. Responders had a mean survival of 345 + days, while non-responders 191.7 days. The treatment was generally well tolerated. In our opinion this combination regimen offers good palliation for patients affected by advanced and/or metastatic non-small cell lung cancer.

yearjournalcountryeditionlanguage
1989-06-01Journal of chemotherapy (Florence, Italy)
10.1080/1120009x.1989.11738891https://pubmed.ncbi.nlm.nih.gov/2552031